Latest News
See all →ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
- Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups
Berlin, Germany,…
ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025
Garching / Munich, Germany, October 17, 2025 -ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced…
Read moreITM Appoints Annette Breunig as Chief People Officer
- Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth
Garching / Munich,…
Read more
